An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803

Trial Profile

An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Biogen Idec
  • Most Recent Events

    • 23 Jun 2009 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
    • 23 Jun 2009 Planned number of patients changed from 1900 to 1615 as reported by ClinicalTrials.gov.
    • 30 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top